GBA1 and lysosomal storage disease: The presence of both polar (piperidine, pyrrolidine, and pyrrolizidine iminosugar analogues) and non-polar hydrocarbon moieties (e.g., miglustat, CHEMBL1029) in the active ingredients used for the treatment of lysosomal storage disorders is strictly associated with the specific interaction of these compounds with glucocerebrosidase (human acid β-glucosidase) active centers [72,73].